PPD® Biotech is a Phase I-IV contract research organization (CRO) service provider devoted to biotech and small to midsize pharma companies.
Expertise in nearly 40 psychiatric and neurological disorders, and clinically trained neuroscience teams led by scientists and clinicians with extensive neuroscience experience.
PPD's Phase I Clinic conducts clinical studies to determine how new medicines act in the bodies of healthy volunteers.
View all of PPD's news releases.
Within pharmacovigilance at PPD, we have implemented various artificial intelligence and machine learning methods that help us and our clients achieve better results.
Gary Barker, Denise Moody, Magda Santos and April Pierce provide insight into creating and keeping a successful pharmacovigilance partnership with a functional service provider.
Brian Brogan, senior logistics manager, provides guidance for clinical trial supply chain requirements post-Brexit and offers some practical solutions for affected U.K.-based life science companies.
Giovanni Monopoli, senior project manager, reflects on what he learned about the eligibility criteria at an American Society of Clinical Oncology (ASCO) conference presentation in 2017.
In the final of a four-part series, Jai Balkissoon, vice president of global product development, writes about the challenges in developing immuno-oncology therapies in combination clinical trials.
We want to hear from you
Register in PPD's Database
© 2018 Pharmaceutical Product Development, LLC. All rights reserved.